Terms: = Ovarian cancer AND LCP1, CP64, 3936, ENSG00000136167, FLJ39956, DKFZp781A23186, L-PLASTIN, FLJ25423, P13796, FLJ26114, PLS2, LC64P AND Treatment
5 results:
1. Recombinant adenoviral vector containing tumor-specific l-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Chung I; Deisseroth AB
Arch Pharm Res; 2004 Jun; 27(6):633-9. PubMed ID: 15283466
[TBL] [Abstract] [Full Text] [Related]
2. Cytotoxic effect of replication-competent adenoviral vectors carrying l-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract] [Full Text] [Related]
3. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma.
Zhang L; Akbulut H; Tang Y; Peng X; Pizzorno G; Sapi E; Manegold S; Deisseroth A
Mol Ther; 2002 Sep; 6(3):386-93. PubMed ID: 12231175
[TBL] [Abstract] [Full Text] [Related]
4. Use of l-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of synthesis of the transformation-induced protein, leukocyte plastin, by ovarian steroid hormones.
Leavitt J; Chen ZP; Lockwood CJ; Schatz F
Cancer Res; 1994 Jul; 54(13):3447-54. PubMed ID: 8012965
[TBL] [Abstract] [Full Text] [Related]
